@article{ad086020143747d78391822eb271d781,
title = "CD8+ T cells: An ineffective armor against prolonged COVID-19 in cancer patients",
abstract = "In a diverse cohort of cancer patients, Lyudovyk et al.1 show that persistent COVID-19 infection is associated with weaker humoral responses and increased CD8+ T cell responses that are ineffective in clearing virus, particularly in patients receiving B cell-depleting therapies.",
author = "{Van Oekelen}, Oliver and Samir Parekh",
note = "Funding Information: S.P. is supported by NCI R01 CA244899, R01 CA252222, and P30 CA196521 and research funding from Bristol Myers Squibb (Celgene), Karyopharm, and Amgen. Funding Information: S.P. is supported by NCI R01 CA244899 , R01 CA252222 , and P30 CA196521 and research funding from Bristol Myers Squibb ( Celgene ), Karyopharm , and Amgen . Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2022",
month = jul,
day = "19",
doi = "10.1016/j.xcrm.2022.100695",
language = "English",
volume = "3",
journal = "Cell Reports Medicine",
issn = "2666-3791",
publisher = "Cell Press",
number = "7",
}